Navigation Links
Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)
Date:10/27/2010

ormation on these clinical trials, please contact the Pfizer Oncology Clinical Trial Information Service at 1-877-369-9753 (US/Canada) or 1-646-277-4066 (international), via email at PfizerHPTrials@emergingmed.com or visit www.pfizercancertrials.com.

Study Results Published in the New England Journal of Medicine

In the Part 2 expansion cohort study which included 82 patients with ALK-positive advanced NSCLC, 57 percent (n=47)(95% CI 46%, 68%) of patients treated with crizotinib (PF-02341066) at a dose of 250 mg twice daily had either a complete or partial response to treatment.  An additional 33 percent (n=27) met criteria for stable disease, including five unconfirmed partial responses.  At eight weeks, the disease control rate (complete response (n=1) + partial response (n=46) + stable disease (n=24)) was 87 percent (n=71).  Three patients with stable disease were not included in the disease control rate because their evaluation for response was outside a pre-specified timeframe.(1)

At the time of the analysis, 77 percent of patients (n=63) continued to receive treatment with crizotinib (PF-02341066).  The median duration of treatment was 6.4 months, and follow-up is ongoing.  

The most commonly reported all-grade adverse events associated with crizotinib included nausea (n=44), diarrhea (n=39), vomiting (n=36), and mild visual disturbances (n=34).  Grade 3 ALT (alanine aminotransferase) and AST (aspartate aminotransferase) elevations occurred in four patients.  One patient experienced a Grade 4 elevation in ALT and one patient discontinued treatment due to Grade 3 ALT increases. Tumors in the analysis were primarily of adenocarcinoma histology, and patients tended to be young, and were never or former light smokers.  Ninety-three percent of patients (n=76)
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , España, September 2, 2014 ... global de fibrilación atrial muestran agentes antitrombóticos no ... -- Las presentaciones de GARFIELD-AF ... sobre el tratamiento y los resultados de pacientes ... clínica diaria --    Los datos ...
(Date:9/2/2014)... , Spanien, September 2, 2014 ... Das auf dem ESC-Kongress 2014 präsentierte ... Behandlung und Behandlungsergebnisse von schlaganfallgefährdeten Patienten ... Die Daten der ... Patienten, einer innovativen und unabhängigen Forschungsinitiative ...
(Date:9/2/2014)... , September 2, 2014 ... CONGRESS 2014 provide insight into treatment and outcomes ... clinical practice --   Data from ... Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, ... prevention strategies for atrial fibrillation (AF) patients remain ...
Breaking Medicine Technology:Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
(Date:9/3/2014)... Washington, D.C. (PRWEB) September 03, 2014 ... issued by GM, Flood Law Group , a ... up to date with the latest information is extremely ... the recalls and is spreading awareness by sponsoring a ... help individuals learn about their legal right to financial ...
(Date:9/3/2014)... Houston, TX (PRWEB) September 03, 2014 7 ... day is sufficient to get people perfect abs within a ... 7 days and will experience the difference not only in ... their vital organs. This has caught the attention of HealthyandFitZone.com’s ... Day Ab TARGETED Solution review shows it is scientific, ...
(Date:9/3/2014)... (PRWEB) September 03, 2014 Health ... increases patient safety, decreases medical errors, and strengthens ... , To mark the important role health information ... IHS and others across the U.S. have joined ... Week , September 16-20, 2014. With the NHIT ...
(Date:9/3/2014)... Morris Psychological Group , PA ... depression on October 9, 2014 from 4:30-8:30 at ... 1,000 organizations nationwide will be hosting National Depression ... installations. After completing a screening, participants will receive ... can offer further evaluation and treatment if necessary. ...
(Date:9/2/2014)... New research reveals that unplanned births out-of-hospital in Norway ... in Acta Obstetricia et Gynecologica Scandinavica , a ... and Gynecology, indicate that young women who have given ... in remote areas are more likely to have unplanned ... newborns. , In 2013, close to 60,000 babies ...
Breaking Medicine News(10 mins):Health News:Flood Law Group Spreads Awareness in Wake of Most Recent GM Recall Announcement 2Health News:7 Day Ab TARGETED Solution: Review Examining Mike Shaun and Karen Hadsall’s Workout Program Released 2Health News:7 Day Ab TARGETED Solution: Review Examining Mike Shaun and Karen Hadsall’s Workout Program Released 3Health News:Innovative Healthcare Solutions (IHS) Celebrates National Health IT Week September, 15-19, 2014 2Health News:Screenings for Depression by Morris Psychological Group, October 9, 2014 from 4:30 to 8:30pm, Rockaway Townsquare Mall (Macy’s Court) 2Health News:Unplanned births out-of-hospital increases risk of infant mortality 2
... film to IDC 1600 Plus X-Series DR, ... Company,Ltd.) (TSX: IDL), the global leader in the ... that HealthPartners Medical Group,of Indiana and Michigan has ... a multi-specialty physician group with facilities in,Michigan City, ...
... WELLINGTON, Fla., June 24 The Quantum Group,(Amex: ... that The Quantum Group of,Companies, namely Renaissance Health ... (FMA) Annual Expo., The FMA represents more ... this annual meeting to provide members with exposure ...
... a Unique Way to Fight Common Illnesses, HOLLYWOOD, ... new web site, http://www.help2getbetter.com, and the sale,of ... household,medicine and fight common illnesses. What makes these sick ... use today, but come packaged,together conveniently in one- or ...
... IRVINE, Calif., June 24 SectorWatch.biz announces the,availability ... in the,news and driving markets today. MarketStats offers ... for investors to respond with,articles and opinions on ... Investors can view MarketStats by visiting: ...
... Services Region of the American Red Cross is facing ... requests of local hospitals. The,morning began with five of ... is zero O-, the universal blood type. In order,to ... the Region should,maintain a minimum three-day supply of all ...
... Easy-to-use formulations help broaden market penetration in China, ... (Amex:,ADL), ( http://www.amdl.com ), a leader in specialty ... anticipates,releasing during the 3rd quarter of 2008 two ... product line. In addition to its,high quality injectable ...
Cached Medicine News:Health News:HealthPartners Medical Group in Michigan City purchases IDC digital radiography system 2Health News:HealthPartners Medical Group in Michigan City purchases IDC digital radiography system 3Health News:The Quantum Group of Companies Exhibits at Statewide Medical Conference 2Health News:The Quantum Group of Companies Exhibits at Statewide Medical Conference 3Health News:Launch of help2getbetter.com Provides Convenience and Portability to Household Medicines 2Health News:SectorWatch.biz Issues MarketStats on Medical Products and Device Companies INCC, CMED, WX, MR and AOB 2Health News:AMDL's Goodnak(R) Anti-Aging Skin Care Line Soon Available in Capsule & Lotion Form 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: